EGFR GENE MUTATION
Clinical trials for EGFR GENE MUTATION explained in plain language.
Never miss a new study
Get alerted when new EGFR GENE MUTATION trials appear
Sign up with your email to follow new studies for EGFR GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to stall lung cancer progression
Disease control OngoingThis study tests whether adding ramucirumab to the standard drug osimertinib can delay cancer growth in people with advanced EGFR-mutant non-small cell lung cancer. About 160 participants who have not had prior targeted therapy will be randomly assigned to receive either the comb…
Matched conditions: EGFR GENE MUTATION
Phase: PHASE2 • Sponsor: Xiuning Le • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
New drug cocktail targets tough cancers with gene mutations
Disease control OngoingThis early-phase study tests a drug called neratinib combined with other drugs (everolimus, palbociclib, or trametinib) in people with advanced solid tumors that have certain gene changes (EGFR, HER2, HER3, HER4, or KRAS) and have stopped responding to standard treatments. The ma…
Matched conditions: EGFR GENE MUTATION
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug combo before surgery shows promise for EGFR-mutant lung cancer
Disease control OngoingThis study tests a two-step treatment approach for people with a certain type of lung cancer (EGFR-mutant, stages II to IIIB). First, patients take a targeted pill (almonertinib), then receive a combination of immunotherapy (adebrelimab) and chemotherapy. After these treatments, …
Matched conditions: EGFR GENE MUTATION
Phase: PHASE2 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New combo therapy shows promise for tough lung cancers
Disease control OngoingThis early-phase trial tests whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for people with stage II or III non-small cell lung cancer that cannot be removed by surgery. The study includes 21 participants and aims…
Matched conditions: EGFR GENE MUTATION
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:54 UTC
-
New combo therapy shows promise for tough lung cancer cases
Disease control OngoingThis study tests whether adding chemotherapy (carboplatin and pemetrexed) to the targeted drug osimertinib helps people with advanced non-small cell lung cancer that has both EGFR and TP53 gene mutations live longer without the cancer growing. About 294 adults who have not had pr…
Matched conditions: EGFR GENE MUTATION
Phase: PHASE3 • Sponsor: Li Zhang, MD • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Smartphone app and fitbit join forces to monitor lung cancer treatment side effects
Knowledge-focused OngoingThis study involves 30 adults with lung cancer who are taking oral targeted therapy (TKIs). Participants use a smartphone app, a Fitbit, and a smart pill cap for up to 24 weeks to track symptoms and medication use. The goal is to see if this remote system is practical and to guid…
Matched conditions: EGFR GENE MUTATION
Phase: NA • Sponsor: University of Virginia • Aim: Knowledge-focused
Last updated May 05, 2026 11:53 UTC